I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
JOURNAL OF NEUROSURGICAL SCIENCES
Rivista di Neurochirurgia
Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,651
Journal of Neurosurgical Sciences 2015 Mar 17
Neuroprotective effects of pregabalin in a rat model of intracisternal facial nerve avulsion
Moriya S. 1, Hasegawa M. 1, Inamasu J. 1, Kogame H. 1, Hirose Y. 1, Higashi R. 2, Ito M. 3, Imai F. 4 ✉
1 Department of Neurosurgery, Fujita Health University, School of Medicine, Toyoake, Japan;
2 Department of Neurosurgery, Komatsu Municipal Hospital, Komatsu, Japan;
3 Department of Pediatric Otolaryngology, Jichi Children's Medical Center Tochigi, Jichi Medical University, Shimotsuke, Japan;
4 Institute of Ichiriyama-Imai Clinic
AIM: Pregabalin (PGB), a drug used for treating neuropathic pain, has immune-modulating property that may have therapeutic implications. Suppression of microglial activation and improvement in functional recovery was observed in experimental spinal cord injury after PGB administration. An experimental study was conducted to evaluate whether PGB could afford neuroprotection in a rat model of intracisternal facial nerve avulsion.
METHODS: Twenty-eight male Wistar rats (250- 300 g) were dichotomized into: PGB group (n=14) and Control group (n=14). The PGB group received a total of 4 intraperitoneal PGB injections (30 mg/kg, 15 min preoperatively and 4 h, 24 h, and 48 h postoperatively), and the Control group underwent intraperitoneal saline injection. Intracisternal facial nerve avulsion was created by tangenital pull-out of the nerve surgically exposed at the stylomastoid foramen. In both groups, the brainstem containing the facial motor nuclei neurons was thin-sliced and stained with cresyl violet, and the number of viable neurons in the facial motor nuclei on Day 14 and Day 28 was counted under microscope.
RESULTS: The total viable neuron count was significantly greater in the PGB group than in the Control group both on Day 14 (271.4±14.9 vs. 196.2±22.2, p <0.01) and Day 28 (160.2±21.6 vs 102.6±13.4, p <0.01). Furthermore, CD11b/c immunostaining on Day 3 and Day 8 showed that CD11b/c-positive cells, suggestive of activated microglia, were observed only in the Control group.
CONCLUSIONS: Better neuronal survival by PGB administration may be beneficial and clinically relevant when surgical reconstruction of the facial nerve, such as hypoglossal-facial nerve anastomosis, is considered.